HIGHLIGHTS
- who: Wang Cao from the leukemia patients in ChinaUniversity, National Center for Children`s Health, Beijing, China have published the research: Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China, in the Journal: (JOURNAL)
- what: This study is the first cost-effectiveness analysis comparing the economic advantages between dasatinib and imatinib for pediatric Ph + ALL patients in China.
- how: Cost and utility From the health system perspective direct health care costs were collected and calculated including the annual costs of TKIs other medical-related . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.